Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ARWR 
Arrowhead Pharmaceuticals Inc (ARWR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: ARWR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.02% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.90B USD | Price to earnings Ratio - | 1Y Target Price 45.64 |
Price to earnings Ratio - | 1Y Target Price 45.64 | ||
Volume (30-day avg) 1433441 | Beta 0.92 | 52 Weeks Range 13.66 - 30.41 | Updated Date 03/30/2025 |
52 Weeks Range 13.66 - 30.41 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6456.48% |
Management Effectiveness
Return on Assets (TTM) -47.71% | Return on Equity (TTM) -565.33% |
Valuation
Trailing PE - | Forward PE 111.11 | Enterprise Value 1870061094 | Price to Sales(TTM) 759.09 |
Enterprise Value 1870061094 | Price to Sales(TTM) 759.09 | ||
Enterprise Value to Revenue 748.02 | Enterprise Value to EBITDA -11.02 | Shares Outstanding 137316992 | Shares Floating 107859280 |
Shares Outstanding 137316992 | Shares Floating 107859280 | ||
Percent Insiders 13.2 | Percent Institutions 74.66 |
Analyst Ratings
Rating 4.13 | Target Price 47.5 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Arrowhead Pharmaceuticals Inc
Company Overview
History and Background
Arrowhead Pharmaceuticals, Inc. was founded in 1989. Initially focused on other areas, it shifted its focus to RNA interference (RNAi) therapeutics in the mid-2000s, developing proprietary delivery platforms. Key milestones include advancements in their TRiM platform and clinical trial progress for various drug candidates.
Core Business Areas
- RNAi Therapeutics: Development and commercialization of RNAi-based therapeutics for various diseases, including liver diseases, cardiometabolic diseases, and other genetic disorders.
Leadership and Structure
The leadership team includes Christopher Anzalone (President & CEO). The company has a typical corporate structure with departments for research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- ARO-AAT (Fazirsiran): A drug candidate targeting alpha-1 antitrypsin deficiency (AATD). Currently in late-stage clinical trials. Competitors include Vertex Pharmaceuticals which acquired Alpine Therapeutics and its AAT inhibitor program in late 2023. Arrowhead has a leadership position based on clinical data.
- ARO-APOC3: A drug candidate targeting APOC3 for the treatment of hypertriglyceridemia. Currently in clinical development. Competitors include Novartis and Ionis Pharmaceuticals.
- ARO-HSD: A drug candidate targeting HSD17B13 for liver diseases. Currently in clinical development.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the RNAi therapeutics sector, is experiencing significant growth. RNAi drugs are showing promise in treating previously untreatable diseases. Gene therapies and CRISPR technologies also compete in this space.
Positioning
Arrowhead Pharmaceuticals is a leader in RNAi therapeutics, particularly with its TRiM platform for targeted delivery to specific tissues. They have a strong pipeline of drug candidates and partnerships with major pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for RNAi therapeutics is estimated to be in the billions of dollars. Arrowhead is well-positioned to capture a significant share of this market through successful clinical trials and commercialization of its drug candidates.
Upturn SWOT Analysis
Strengths
- Proprietary TRiM platform for targeted RNAi delivery
- Strong pipeline of drug candidates
- Partnerships with major pharmaceutical companies
- Experienced management team
- Promising clinical trial results
Weaknesses
- Dependence on successful clinical trials
- High research and development costs
- Regulatory hurdles
- Relatively small commercialization infrastructure
Opportunities
- Expanding pipeline to address additional diseases
- Securing regulatory approvals for key drug candidates
- Expanding partnerships with pharmaceutical companies
- Advancing delivery technologies
- Potential for future acquisitions
Threats
- Clinical trial failures
- Competition from other RNAi and gene therapy companies
- Patent disputes
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- ALNY
- IONS
- VRTX
Competitive Landscape
Arrowhead has a strong platform for targeted RNAi delivery. Alnylam is the market leader with approved RNAi therapies. Ionis focuses on antisense oligonucleotide (ASO) therapies, another class of nucleic acid drugs. Vertex is focusing on AAT deficiency drugs.
Major Acquisitions
Visirna Therapeutics
- Year: 2021
- Acquisition Price (USD millions): 25
- Strategic Rationale: Expanded Arrowhead's clinical pipeline and access to intellectual property related to RNAi therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Arrowhead's growth has been driven by advancements in its RNAi platform and the progression of its drug candidates through clinical trials.
Future Projections: Future growth is projected to be driven by regulatory approvals and commercialization of key drug candidates, as well as new partnership agreements. Analyst estimates vary depending on the probability of success for its pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for ARO-AAT, ARO-APOC3, and ARO-HSD, as well as expanding its research and development efforts to explore new therapeutic areas.
Summary
Arrowhead Pharmaceuticals is a promising biotech company focused on RNAi therapeutics and has a leading platform. Clinical successes and partnerships drive shareholder value. Regulatory hurdles, competition, and reliance on clinical data represent the company's primary challenges which it must address in order to remain competitive. Arrowhead is well positioned for long-term growth within the promising RNAi therapeutic space.
Similar Companies
- ALNY
- IONS
- VRTX
- MRNA
Sources and Disclaimers
Data Sources:
- Arrowhead Pharmaceuticals Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry News Sources
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Actual results may vary significantly from projections. Market share data is approximate and based on available industry reports and estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arrowhead Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 1993-06-16 | Chairman, CEO & President Dr. Christopher R. Anzalone Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 609 | Website https://arrowheadpharma.com |
Full time employees 609 | Website https://arrowheadpharma.com | ||
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.